Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on May 17, 2010. The registrant is a Delaware corporation headquartered in Annapolis, Maryland. The filing reports a corporate governance event rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Eric I. Richman, 49, to the Board of Directors. Mr. Richman was previously serving as the company's President and interim Chief Executive Officer.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to the disclosure of the director appointment under Item 5.02.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata referenced Altimmune, Inc.
- Confirm the effective date of Eric I. Richman's appointment to the Board of Directors (May 17, 2010).
- Review subsequent filings for financial data, as this 8-K contains no financial metrics.